Grayson-Jockey Club Research Foundation announced today that it has issued a formal call for research applications focused on the development of a nucleic acid-based vaccine against equine herpes virus (EHV). Dr. John Ballantyne and Fargo-Moorhead Area Foundation have committed $2 million to fund this research.
“We are so grateful to Dr. Ballantyne for his generosity in supporting efforts to address EHV, a disease that affects all horses,” said Dell Hancock, chair of the foundation. “This gift will enable Grayson to continue its commitment to funding critical research for horses, and our research advisory committee looks forward to seeing what proposals are submitted.”
“As a horse owner with a biotechnology background, I recognize the danger of EHV and see the potential for nucleic acid-based vaccines for combating this disease,” said Dr. Ballantyne. “I am proud to work with Grayson to support EHV research.”
Grayson is interested in research proposals focused on EHV-1, EHV-3, and EHV-4, with a multivalent or pan-valent approach. Researchers must have the ability to conduct an in vivo proof of principle of efficacy in the equine model in-house or through collaboration. Applications from established equine investigators collaborating with experts from other fields (e.g., human vaccinologists) are strongly encouraged. It is anticipated that this research will span three to four years and possibly multiple projects.
Grant applications are due October 1, 2022 and can be submitted at grayson-jockeyclub.org.
Grayson-Jockey Club Research Foundation is traditionally the nation’s leading source of private funding for equine medical research that benefits all breeds of horses. Since 1983, the foundation has provided more than $30.6 million to fund 397 projects at 45 universities in North America and overseas. Additional information about the foundation is available at grayson-jockeyclub.org.